Pharmacy Reports
Vol. 2 No. 1 (2022): Pharmacy Reports

The potency of alpha-humulene as HER-2 inhibitor by molecular docking

Putra, I Made Harimbawa (Unknown)
Pratama, I Putu Ari Anggara Catur (Unknown)
Putra, Komang Dian Aditya (Unknown)
Pradnyaswari, G. A. Desya (Unknown)
Laksmiani, Ni Putu Linda (Unknown)



Article Info

Publish Date
12 Jan 2022

Abstract

HER-2 overexpression is present in approximately 20% of breast cancer. This research aims to study the interactions of α-humulene to HER-2 protein by using in silico molecular docking. The experiment was carried out by HER-2 protein preparation (PDB ID 3PP0), docking validation, α-humulene optimization, and α-humulene docking. The results showed that α-humulene had binding energy of -7.50 kcal/mol, Van der Waals binding energy of -7.48 kcal/mol, and electrostatic energy of -0.02 kcal/mol. α-Humulene is potential as anti-breast cancer towards HER-2 in silico.

Copyrights © 2022






Journal Info

Abbrev

pharmrep

Publisher

Subject

Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology

Description

Pharmacy Reports is an open-access journal publishing peer-reviewed research in the pharmacy field, covering topics in pharmaceutics, biomedicine, pharmaceutical chemistry, bioinformatics, natural product, pharmacology and toxicology, and clinical pharmacy. Pharmacy Reports invites you to submit ...